tetano
Editor, Senior Moderator
J Vis Exp. 2017 Jan 30;(119). doi: 10.3791/54312.
[h=1]Rapid Molecular Detection and Differentiation of Influenza Viruses A and B.[/h] Otto CC[SUP]1[/SUP], Kaplan SE[SUP]1[/SUP], Stiles J[SUP]1[/SUP], Mikhlina A[SUP]1[/SUP], Lee C[SUP]1[/SUP], Babady NE[SUP]1[/SUP], Tang YW[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza is a contagious respiratory illness caused by influenza viruses A and B in humans and causes a significant amount of morbidity and mortality every year. The Influenza A and B assay was the first CLIA-waived molecular rapid flu test available. The Influenza A and B test works by employing isothermal amplification with influenza-specific primers followed by target detection with molecular beacon probes. Here, the performance of the Influenza A and B assay on frozen, archived nasopharyngeal swab (NPS) specimens stored in viral transport medium (VTM) were compared to a respiratory panel assay. The performance of the Influenza A and B assay was evaluated by comparing the results to the respiratory panel reference method. The sensitivity for total influenza virus A was 67.5% (95% CI (CI), 56.6-78.5) and the specificity was 86.9% (CI, 71.0-100). For influenza virus B testing, the sensitivity and specificity were 90.2% (CI, 68.5-100) and 98.8% (CI, 68.5-100), respectively. This system has the advantage of a significantly shorter test time than any other currently available molecular assay and the simple, pipette-free procedure runs on a fully integrated, closed, small-footprint system. Overall, the Influenza A and B assay evaluated in this study has the potential to serve as a point-of-care rapid influenza diagnostic test.
PMID: 28190065 DOI: 10.3791/54312
[PubMed - in process]
[h=1]Rapid Molecular Detection and Differentiation of Influenza Viruses A and B.[/h] Otto CC[SUP]1[/SUP], Kaplan SE[SUP]1[/SUP], Stiles J[SUP]1[/SUP], Mikhlina A[SUP]1[/SUP], Lee C[SUP]1[/SUP], Babady NE[SUP]1[/SUP], Tang YW[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza is a contagious respiratory illness caused by influenza viruses A and B in humans and causes a significant amount of morbidity and mortality every year. The Influenza A and B assay was the first CLIA-waived molecular rapid flu test available. The Influenza A and B test works by employing isothermal amplification with influenza-specific primers followed by target detection with molecular beacon probes. Here, the performance of the Influenza A and B assay on frozen, archived nasopharyngeal swab (NPS) specimens stored in viral transport medium (VTM) were compared to a respiratory panel assay. The performance of the Influenza A and B assay was evaluated by comparing the results to the respiratory panel reference method. The sensitivity for total influenza virus A was 67.5% (95% CI (CI), 56.6-78.5) and the specificity was 86.9% (CI, 71.0-100). For influenza virus B testing, the sensitivity and specificity were 90.2% (CI, 68.5-100) and 98.8% (CI, 68.5-100), respectively. This system has the advantage of a significantly shorter test time than any other currently available molecular assay and the simple, pipette-free procedure runs on a fully integrated, closed, small-footprint system. Overall, the Influenza A and B assay evaluated in this study has the potential to serve as a point-of-care rapid influenza diagnostic test.
PMID: 28190065 DOI: 10.3791/54312
[PubMed - in process]